Document is current
Any future updates will be listed below
-
Authors
Keck, Michaela-Kristina
Al-Hussaini, Maysa
Amayiri, Nisreen
Yiadom, Akosua Adoma Boakye
Chamyan, Gabriel
Cheesman, Edmund
Faure-Conter, Cécile
Garcia-Ariza, Miguel
Gauchotte, Guillaume
Hasselblatt, Martin
Jorgensen, Mette
Kilday, John-Paul
Lamas, Gabriela
Lavarino, Cinzia
Li, Marilyn M.
Lubieniecki, Fabiana
Maher, Ossama M.
Meyronet, David
Mueller, Jan
Santi, Mariarita
Schüller, Ulrich
Seidinger, Ana Luiza
Sill, Martin
Sudhakar, Sniya
García, María Tallón
Tauziede-Espariat, Arnault
Varlet, Pascale
Vasiljevic, Alexandre
Wittmann, Andrea
von Deimling, Andreas
Solomon, David A.
Sahm, Felix
Tietze, Anna
von Hoff, Katja
Sievers, Philipp
Jones, David T. W.
-
Funding
Funding for this research was provided by:
SEHOP-PENCIL study - Personalized mEdiciNe for Cancer in chILdren in Spain (PMP21/00075)
Fördergemeinschaft Kinderkrebszentrum Hamburg
PRONON program (25.000.069610/2015-43)
Morgan Adams Foundation
Yuvaan Tiwari Foundation
Else Kröner-Fresenius-Stiftung
Brain Tumour Charity (GN-000707)
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 8 May 2025
Revised: 10 July 2025
Accepted: 20 July 2025
First Online: 2 August 2025
Declarations
:
: D.T.W.J., F.S., and A.v.D. are co-founders and shareholders of Heidelberg Epignostix GmbH.
